Two Phase III Trials of Baricitinib for Alopecia Areata: A Critically Appraised Research Paper

    October 2022 in “ British Journal of Dermatology ”
    Sheila M. McSweeney, Tuntas Rayinda, John A. McGrath, Christos Tziotzios
    Studysummary This study reports that two phase III trials demonstrated the effectiveness of the oral Janus kinase inhibitor baricitinib at 2 mg or 4 mg daily for treating severe alopecia areata in adults, marking a potential advance in managing this condition.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on doi.org →
    Discuss this study in the Community →

    Research cited in this study 3

    1. Analysis of Alopecia Areata Surveys Suggests a Threshold for Improved Patient-Reported Outcomes British Journal of Dermatology · 2022
    2. Two Phase 3 Trials of Baricitinib for Alopecia Areata The New England Journal of Medicine · 2022
    3. Alopecia Areata and Health-Related Quality of Life: A Systematic Review and Meta-Analysis British Journal of Dermatology · 2016

    Related research 1

    1. Twenty Nail Dystrophy with Alopecia Areata in an Atopic Child International journal of research in dermatology · 2019